Phase 3 Trial Of Crenessity (Crinecerfont) In Pediatric Congenital Adrenal Hyperplasia
The U.S. Food and Drug Administration (FDA) has approved Crenessity™ (crinecerfont) as an adjunctive treatment…
News
FDA Approves Alhemo: A Breakthrough In Hemophilia Treatment
In a significant advancement for hemophilia care, the U.S. Food and Drug Administration (FDA) has…
Beovu For Diabetic Macular Edema: A New Era In Retinal Disease Treatment
In a significant advancement for retinal disease management, the U.S. Food and Drug Administration (FDA)…
Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List Price
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a…
Cablivi’s 2025 Outlook: Advancements And Challenges In Treating ATTP
In 2025, Sanofi’s Cablivi (caplacizumab-yhdp) continues to play a pivotal role in the management of…
Lybalvi Offers Safer Option For Patients With Schizophrenia And Bipolar I Disorder
Lybalvi (olanzapine/samidorphan), a new antipsychotic drug approved by the U.S. Food and Drug Administration (FDA)…
FDA Approves Lytgobi For Treatment Of Intrahepatic Cholangiocarcinoma With FGFR2 Gene Abnormalities
The U.S. Food and Drug Administration (FDA) has approved a novel targeted drug, Lytgobi (Futibatinib),…
Minjuvi (Tafasitamab) Approved For Marketing In Mexico Brings New Hope To Patients with Refractory Lymphoma
March 2025 Knight Therapeutics announced that its anti-CD19 monoclonal antibody drug Minjuvi (tafasitamab) has been…
Mounjaro Breakthrough In Diabetes Treatment With Launch Of Glucose-Lowering Drug Mounjaro
The U.S. Food and Drug Administration (FDA) recently approved the marketing of Mounjaro® (Tirzepatide), a…
Nurtec ODT (Rimagipam): The Dual-Action Oral Dissolving Tablet That Revolutionizes Migraine Treatment
Migraines afflict more than one billion people worldwide, and their attacks of severe headache, light…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights